🧬Tidera Health
⚕️

Educational tool only. Does not confirm eligibility or provide medical advice. Always consult your physician before pursuing any trial.

RheumatologyICD-10: M07

Find Recruiting Clinical Trials for Psoriatic Arthritis

Search PsA trials for biologic-naive and biologic-experienced patients — IL-17, IL-23, JAK, and TYK2 inhibitor studies.

🔍 Search Psoriatic Arthritis Trials →

About Psoriatic Arthritis

Psoriatic arthritis (PsA) is a chronic inflammatory arthritis occurring in 20–30% of people with psoriasis. It is characterized by peripheral joint inflammation, enthesitis (tendon/ligament insertion inflammation), dactylitis (sausage digits), axial involvement, and associated skin disease. Treatment has been transformed by biologics targeting TNF, IL-17A, IL-23, and the JAK/TYK2 pathways. Despite multiple approved agents, 40–50% of patients do not achieve adequate disease control.

What Types of Psoriatic Arthritis Clinical Trials Exist?

PsA clinical trials test next-generation IL-17 inhibitors, IL-23 inhibitors, TYK2 inhibitors, selective JAK inhibitors, and novel oral small molecules. Trials stratify patients by prior biologic exposure (naive vs. experienced), disease domain (predominantly peripheral, axial, enthesitis-predominant, or skin-predominant), and biomarker profiles. ACR20/50/70 response criteria and PASI scores for skin are standard endpoints.

Find Recruiting Psoriatic Arthritis Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time — matching trials to your age, location, and treatment history. Free, no account required.

Search Psoriatic Arthritis Trials →

Data from ClinicalTrials.gov · Updated in real time · Educational use only

Frequently Asked Questions

What clinical trials are available for psoriatic arthritis?▾
Recruiting PsA trials include IL-17 inhibitors, IL-23 inhibitors, TYK2 inhibitors (deucravacitinib), selective JAK inhibitors, and combination regimens. Many trials specifically enroll biologic-naive patients or patients who have failed one or more anti-TNF or IL-17 therapies.
Does my biologic history affect PsA trial eligibility?▾
Yes significantly. Trials are stratified by prior biologic exposure. Biologic-naive trials test new agents as first-line therapy. Biologic-experienced trials enroll patients with inadequate response, loss of response, or intolerance to one or more approved biologics. The number and mechanism of prior failed biologics matters.
Do I need both psoriasis and joint disease to qualify for PsA trials?▾
Most PsA trials require a confirmed PsA diagnosis (by CASPAR criteria), which includes active arthritis in the context of psoriatic disease. Active joint disease (swollen and tender joint counts) is typically required. Some trials also require active skin disease (BSA ≥3% or PASI ≥12), while others focus primarily on joint endpoints.

Related Conditions

PsoriasisRheumatoid ArthritisAnkylosing Spondylitis

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.